Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

S. Vasconcelos

2 papers in the library · publishing 2018-2020

Papers

Rapid and long-lasting antidepressant-like effects of ketamine and their relationship with the expression of brain enzymes, BDNF, and astrocytes

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas December 18, 2020 G.S.B. Viana, E.M. Do Vale, Ana Giullia de Alencar Araújo et al.

A single oral dose of ketamine (5 or 10 mg/kg) produced rapid (30 minutes) and long-lasting (up to 30 days) antidepressant-like effects in male Swiss mice, measured by the forced swim test. The tricyclic antidepressant imipramine served as a reference. Ketamine reduced immunoreactivity for GSK-3 and HDAC in several brain regions, especially the prefrontal cortex, and increased BDNF immunostaining in the prefrontal cortex, dentate gyrus, CA1, and CA3 areas at both 1 and 30 days after injection. GFAP immunoreactivity also increased in the prefrontal cortex and striatum at both time points. The authors conclude that ketamine alters brain BDNF and GFAP expression for 30 days after a single dose, but further studies are needed to explain the mechanisms of its sustained effects.

Ethanolic extract of Erythrina velutina Willd ameliorate schizophrenia-like behavior induced by ketamine in mice

Journal of Complementary and Integrative Medicine October 12, 2018 N. C. Ximenes, Manuel Alves Dos Santos Junior, G. S. Vasconcelos et al.

An extract from the stem bark of the plant Erythrina velutina (EEEV), known as “mulungu,” reversed schizophrenia-like behaviors in mice that had been induced by repeated ketamine injections. Mice given ketamine for 14 days showed deficits in prepulse inhibition of the startle reflex, hyperlocomotion, and impaired social interaction. When EEEV extract (200 or 400 mg/kg) was given alongside ketamine from days 8 to 14, it reversed these behavioral changes, similar to the effects of the antipsychotic olanzapine. The results suggest EEEV may offer a new avenue for developing schizophrenia treatments.